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ABSTRACT: A mass spectrometry-based plasma biomarker
discovery workflow was developed to facilitate biomarker
discovery. Plasma from either healthy volunteers or patients
with pancreatic cancer was 8-plex iTRAQ labeled, fractionated
by 2-dimensional reversed phase chromatography and
subjected to MALDI ToF/ToF mass spectrometry. Data
were processed using a q-value based statistical approach to
maximize protein quantification and identification. Technical
(between duplicate samples) and biological variance (between
and within individuals) were calculated and power analysis was
thereby enabled. An a priori power analysis was carried out
using samples from healthy volunteers to define sample sizes
required for robust biomarker identification. The result was
subsequently validated with a post hoc power analysis using a
real clinical setting involving pancreatic cancer patients. This
demonstrated that six samples per group (e.g., pre- vs post-
treatment) may provide sufficient statistical power for most proteins with changes >2 fold. A reference standard allowed direct
comparison of protein expression changes between multiple experiments. Analysis of patient plasma prior to treatment identified
29 proteins with significant changes within individual patient. Changes in Peroxiredoxin II levels were confirmed by Western
blot. This q-value based statistical approach in combination with reference standard samples can be applied with confidence in
the design and execution of clinical studies for predictive, prognostic, and/or pharmacodynamic biomarker discovery. The power
analysis provides information required prior to study initiation.
KEYWORDS: mass spectrometry, plasma proteomics, biomarkers, power analysis
■ INTRODUCTION
Discovery of novel biomarkers using minimally invasive
approaches is increasingly required to expedite drug develop-
ment in the era of mechanism-based therapeutics and patient
stratification.
1 Achieving high confidence in the discovered
biomarkers is a major challenge for clinical researchers,
highlighted by a dearth of successful biomarker validation
recently. Difficulties in validating tissue and blood borne
biomarkers include the lack of availability of patients’ samples,
the lack of consistency in sample collection, heterogeneity in
patient populations and current technological limitations. The
development of plasma biomarkers is attractive as repeat
sample collection is simple and minimally invasive.
1
Human biological variation and the considerable range in
specific protein concentrations within plasma present a
challenge to quantitative biomarker discovery. Advances in
mass spectrometry (MS)-based proteomic technologies have
resulted in an increased ability to quantify and overcome such
issues with careful experimental design. We have previously
used an 8-channel isobaric tagging method (iTRAQ)
2 coupled
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mass spectrometry (MS/MS) to quantify proteins.
3 This has
been shown to be a sensitive proteomic quantification method.
4
For successful biomarker discovery, a procedure to address
correctly formulated clinical research questions where power
analysis is absolutely essential to experimental design is
required.
5 Furthermore, the sample sizes for such studies
(MS-based or otherwise) must be feasible to allow large-scale,
longitudinal clinical studies to be conducted with a high
probability of identifying biomarkers with confidence. Several
studies have highlighted the promise of 4 channel iTRAQ as a
tool for identifying potential biomarker signatures of disease
and potentially of drug response using serum, plasma,
cerebrospinal fluid and tissue.
6−10
Isobaric tag comparisons are typically analyzed with respect
to experimentally determined thresholds where a change in
protein expression outside this range is deemed to be
significant.
11,12 However, false positive error (protein incor-
rectly determined as differentially expressed) or false negative
error (protein that is truly differentially expressed not detected)
can result. The power of a test is its ability to correctly lead to
the rejection of the null hypothesis: the ability to detect an
effect, if the effect exists. This depends on specific factors
including variance in protein expression, effect size (the change
in protein expression), number of replicates, and the
significance level required. Therefore, to increase the power
in an experiment, the number of replicates must be sufficient to
distinguish between true differences and random effects. Too
many replicates can be an unnecessary waste of time and
Figure 1. Design of the 8 channel isobaric tagging experiments for relative quantification of proteins from plasma. (A) Methodological workflow of
sample analysis. Plasma depletion was achieved using an antibody based removal of the 20 major proteins found in human plasma. This was followed
by tryptic digestion of the analyte and peptide tagging in the 8 different samples with 8 distinct isobaric tags that enable relative quantification of
peptides from the 8 samples by tandem mass spectrometry. Peptides from the 8 samples were pooled and then fractionated using high pH reverse
phase liquid chromatography (LC). Fractions were then spotted onto MALDI target plates by low pH RP LC and plates were analyzed by MSMS in
5800 MALDI ToF/ToF instrument (Applied Biosystems). A number of data manipulations were then performed to assess the value of the workflow.
(B) Experimental setup and labeling. In Experiment 1, plasma from healthy individuals was taken 16 h apart and processed and analyzed in duplicate
to assess technical and biological (within and between person) variation. In experiments 2 and 3, plasma was isolated from patients enrolled in the
PACER pancreatic cancer trial at the Christie Hospital, Manchester, U.K. and 2 pretreatment samples were taken one week apart. To compare across
experiments, a pooled reference control was used (pool) containing an aliquot of all plasma samples from experiments 2 and 3 points prior to sample
depletion and in a 1:1 ratio for all samples.
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protein changes with statistical significance. The strength of
including an evaluation of statistical power to enhance the
experimental design of proteomic studies has been highlighted.
5
We have extended this analysis to 8 channel relative
quantification for detecting changes in plasma protein
abundance. Using data sets derived from healthy controls, we
have carried out a power analysis that provides us with guidance
for future clinical studies. These results have been subsequently
validated using data sets from pancreatic cancer patients. In
addition, we have validated our method to allow interexperi-
ment comparability via reference standards generating the first
gel free proteomic approach with power analysis for direct
application to clinical trials.
■ MATERIALS AND METHODS
Technical Workflow
An overview of the complete workflow used in this study is
shown in Figure 1A.
Experimental Design
Using the workflow summarized in Figure 1A, three iTRAQ
experiments were performed to meet the study objectives
(Figure 1B). We first examined the technical, temporal and
biological variation between samples. A positively identified
protein had to meet stringent criteria based on statistical
considerations using approaches designed to minimize the
number of false positive identifications. Technical variability
was determined by analysis of four replicate plasma samples
from two healthy human controls processed independently
under identical conditions and run as a single multiplexed 8
channel iTRAQ experiment (Experiment 1). These data were
then used in a power calculation to evaluate the suitability of
this workflow for future clinical studies.
Guided by the a priori power analysis from Experiment 1, the
second two experiments were carried out interrogating samples
derived within the PACER -TRANS substudy to the PACER
clinical trial (Christie Hospital, Manchester, U.K.). PACER is a
phase II study of high dose rate radiotherapy and EGFR
inhibitor monoclonal antibody erbitux (Cetuximab) in patients
with locally advanced pancreatic cancer. Prior to treatment,
blood samples were collected from patients at two different
time points with one week apart (day 0 and day 7, Experiments
2 and 3; Figure 1B). The objective is to identify proteins that
are differentially expressed in the 7 day period and carry out a
post hoc power analysis which allowed us to explore the validity
of the a priori power calculation using Experiment 1.
Furthermore the study design will address use of a pooled
reference sample, created by mixing part of each sample used in
Experiments 2 and 3. This would allow the direct comparison
of protein changes determined from different 8-plex exper-
imental runs, essential for the future of large scale trial analyses
conducted by this method.
Human Plasma Samples
Blood was collected from donors in lithium heparin coated
tubes (BD Vacutainer) and centrifuged within 30 min of
collection at 2500× g for 15 min at 4 °C before aliquots of the
plasma layer were stored at −80 °C. Samples were collected at
two different time points for each patient and healthy
volunteer. For healthy volunteers samples were collected 16 h
apart. Blood samples were taken from 3 patients with
pancreatic cancer enrolled in the PACER study at the Christie
Hospital, Manchester, UK (ref.06/Q1407/17) following
written informed consent with ethical approval from the
Central Manchester Local Research Ethics Committee. Two
blood samples were taken one week apart, prior to patients
receiving any therapy. Pooled samples were created prior to
depletion by the accumulation of 50 μL of each plasma sample
from all three pancreatic patients at both time points (Figure
1B).
Protein Depletion, Digestion and Labeling
Abundant proteins were removed from plasma using a Sigma
Top20 spin column following the manufacturers’ protocol
(Sigma Aldrich). Depleted samples were concentrated and
buffer-exchanged into 1 M TEAB using Vivaspin 500
centrifugal concentrators (Sigma Aldrich) as per manufacturer’s
instructions. The protein concentration in buffer-exchanged
samples was measured using the 2-D Quant kit (Amersham
Bioscience, Buckinghamshire). Fifty μg of each sample was
reduced with the addition of 1/10th of the sample volume of 50
mM tris(2-carboxyethyl)phosphine for 1 h at 60 °C. Cysteine
residues were then alkylated by the addition of 1/20th of the
total sample volume 200 mM Methyl thiomethanesulfonate (in
isoproponol) before incubation for 10 min at room temper-
ature. Protein was digested by the addition of 5 μg of porcine
trypsin (Sigma Aldrich) with 15 min in a CEM discoverer
microwave at 55 °C (CEM, North Carolina) to aid digestion,
followed by overnight at 37 °C. The digested protein samples
were labeled with 8plex iTRAQ reagents according to the
manufacturers’ instructions (Applied Biosystems, Foster City,
CA). After labeling the samples were dried at 60 °Ci na
SpeedVac and then stored at −20 °C. Samples were labeled
according to Figure 1B.
High pH Reverse Phase (RP) Chromatography
iTRAQ labeled samples were reconstituted in 100 μL of 0.1%
Ammonium hydroxide (Solvent A) and pooled prior to being
loaded onto a 100 × 4.6 mm 3 μm C18 HPLC column (Fortis,
Cheshire, UK). Peptides were eluted by the application of a
linear 30 min gradient up to 50% solvent B (Acetonitrile, 0.1%
Ammonium hydroxide) with 70 × 15 s fractions collected from
4 min. Fractions were dried in a SpeedVac at 60 °C and stored
at −20 °C.
Liquid Chromatography (LC)
Dried samples were reconstituted in 130 μL of 0.1% TFA, 2%
ACN. Half of the sample was loaded onto a trap column using a
U3000 liquid chromatography system (Dionex, Sunnyvale, CA)
and the peptides fractionated by a capillary RP C18 HPLC
column (Acclaim PepMap C18, 3 μM 100 Å) at a flow rate of
0.8 μL/min with a gradient of between 2 and 40% acetonitrile,
0.1% TFA. The flow-through was spotted onto a MALDI plate
(AB SCIEX, Foster City, CA) in 15 s fractions using an online
Probot (Dionex, Sunnyvale, CA) with α-cyano-4-hydroxycin-
namic acid mixing with the eluent to a final concentration of
1.25 mg/mL.
Mass Spectrometry (MS/MS)
Mass spectrometry was carried out on an AB Sciex TOF/TOF
5800 (AB Sciex, Foster City, CA, USA) using 1000 shots for
MS. MS/MS was carried out on the top 27 precursors with a S/
N of higher than 8 using 4000 laser shots, a 2Kv acceleration
voltage and air as the collision gas. MS/MS spectra were
smoothed using the Savitsky Golay Algorithm with 3 points
and 4 orders of magnitude.
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All MS/MS data were submitted to ProteinPilot software
version 3.0 (Applied Biosystems) for database searching and
iTRAQ reporter ion quantification. Searches were performed
against the IPI Human (v3.59) protein sequence database,
containing 160248 protein sequences. A reversed database was
searched at the same time to control the false discovery rate
(FDR) of protein identification (see below). Cys alkylation
with methanethiosulfate (MMTS) and trypsin as the digestion
enzyme were specified in the search. Biological modifications
and amino acid substitutions were also permitted. ProteinPilot
uses the Pro Group Algorithm to ensure that any peptide ID is
only represented by one protein ID.
False Discovery Rate of Protein Identification
The FDR of protein identification was calculated using a target-
decoy searching strategy
13 where forward and reverse
sequences from the database were in equal competition to be
the highest ranking identification for each spectrum. The q-
value
14 approach was then used to define a peptide confidence
threshold at which to call PSMs significant as to minimize false
positives. The protein level FDR was estimated using the
method reported by Kall et al.
15 The maximum allowed peptide
FDR and protein FDR are set to 1% and 5% respectively.
Protein Quantification
Peptides with no quantification, absence of one or more
reporter ions, low signal-to-noise ratio or with confidence <1%
were not used. If peptides were only partially enzymically
hydrolyzed, missing an iTRAQ reagent label, or contained a
low probability modification then they were also removed.
Additionally, peptides shared among related, but distinct
proteins or peptides where the spectrum is also matched to a
different protein with unrelated peptide sequence were not
used in quantification. Remaining peptides were included as
contributing factors to protein quantification. Further, if a
protein contained no peptides above the peptide confidence
threshold determined by q-value analysis, it was judged to have
failed identification and quantification and subsequently
excluded from the final data set. Protein quantification was
then calculated manually as per ProteinPilot software:
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where xi is the log(peptide ratioi) for the ith observation, wi is
the weight for the ith observation normalized against the
percentage error under the peak to remove biases cause by label
differences. Finally, n is the number of contributing peptides to
a protein’s average ratio.
MS Variation
The unweighted standard deviation (Std) of each protein ratio
was calculated using the following equation from ProteinPilot:
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where xi is the log(peptide ratioi) for the ith observation, xavg is
the unweighted average of xi and n is the number of peptide
ratios contributing to a protein’s average ratio. The average of
all Stds calculated from each protein identified and quantified
was then used as an estimate of the MS variation.
Sample Size Determination
Sample size calculations were based on the normal linear mixed
effects model as described previously.
16−18 The log2 ratio
represented the ratio change between the iTRAQ labels. The
effect size was calculated as follows, where rep1 refers to
replicate 1 and rep2 refers to replicate 2.
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For example, for a 2 fold change, the effect size = log2(2) = 1.
Therefore the null hypothesis is:
= effect size 0
We will accept or reject this hypothesis according to the
observed experimental data.
The approach utilized by Dobbin and Simon
20 for sample
size calculations in microarrays was adopted such that the log2
ratio of each protein p had variance across all samples within a
group of interest composed of both technical (σp
2) and
biological (τp
2) variance. In a two-group problem (e.g., pre- vs
post-treatment) the total number of biologically distinct
samples n in each class is given by:
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where m is the number of technical replicates per sample, δ is
the difference in class means or observed effect size. zα/2 and zβ
are the 100α/2th and 100βth percentiles of the normal
distribution. These are specified by the significance level α
and the power 1 − β that we wish to base our hypothesis
around.
Technical variance (σp
2) was estimated from four replicate
plasma samples processed identically and run as a single
iTRAQ MS/MS experiment. This allowed for an assessment of
variation caused by the experimental workflow, where ideally
ratios of all the proteins quantified should be 1. The technical
replicates were 114:113, 116:115, 118:117 and 121:119.
Biological variation (τp
2) comprises within person variation
and between person variation. Using technical variation and
within person variation, proteins that are differentially ex-
pressed within a specific patient can be derived. With the
additional between person variation, proteins that are differ-
entially expressed in all patients can be derived. These proteins
can be used as candidates for biomarkers. In Experiment 1,
within person variance was estimated using the within person
variation across a 16 h time period, and between person
variance was estimated using the between person variation
among the two healthy donor controls. Any deviations from a
ratio of 1 would provide information regarding natural
variation. Of course, the observed biological variation naturally
contains the component from technical variation which should
be excluded before power analysis.
iTRAQ Workflow Reproducibility
The same pooled reference was used for both PACER 0 day
and PACER 7 day experiments to allow for direct comparison
of protein ratios across two separate runs of the complete
workflow. iTRAQ ratios for the reference labels in proteins
quantified in both experiments were compared using the Bland-
Altman comparison, and assessed statistically with Pitman’s test
of difference in variance (Stata 10.1, StatCorp LP).
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One μg of undepleted plasma was diluted 10-fold in 10 mM
phosphate buffered saline (PBS), followed by the addition of
2× Laemmli buffer (Bio-Rad Laboratories, Hemel Hempstead,
U.K.) and heated at 95 °C for 20 min prior to SDS-PAGE in
10% polyacrylamide gels. Proteins were transferred onto PVDF
membranes (Perkin-Elmer, Waltham, MA), incubated in 1%
(w/v) Non-Fat Milk in 10 mM PBS-Tween(T) (0.1% w/v)
followed by incubation with either mouse Anti-Peroxiredoxin II
1:3000 in 1% (w/v) Non-Fat Milk in PBS-T (1E8 Ab Frontier,
Korea) or Rabbit Anti-Coagulation Factor XIII B Chain
Precursor (F13B) 1:1000 (HPA003827 Sigma Prestige Anti-
bodies, St Louis, MO) and a horseradish peroxidase-coupled
antimouse or antirabbit secondary IgG (Dako, Glostrop,
Denmark). This was followed by detection with the Western
Lightning Chemiluminescence Reagent Plus (Perkin-Elmer).
■ RESULTS
Parameters for Protein Identification in 8 Channel Plasma
Proteomics
Experiment 1 involved samples from healthy donor controls
(Figure 1B) and in this experiment 85306 mass spectra were
matched after simultaneous searching of proteins against the
International Protein Index reversed target decoy database,
resulting in a peptide FDR of 24%. Within these peptides, 8003
spectra were quantifiable which resulted in 493 nonredundant
proteins. The inclusion of low confidence peptides in protein
identification/quantification led to an FDR of 6.7%. In such
experiments there is a need to control for the FDR, thus a q-
value approach was implemented
21 (see Methods) whereby
peptides were filtered based upon different confidence
thresholds prior to their use in identification and quantification,
thereby low confidence peptides could be excluded from
further analyses and the FDR could be set at an appropriate
value (Table 1).
It was evident that the use of different q-value thresholds
varied the number of matches selected as significant
(Supplementary Figure 1, Supporting Information). We
found that a minimum peptide confidence of 91% was required
to ensure that the false positive proportion of significant
peptide spectral matches (PSMs) was <0.01 after correction for
multiple testing (Table 1). A single 8 channel isobaric-tagged
peptide identified with above 91% confidence was thus shown
to be evidence for protein identification and quantification.
Those proteins identified with no quantified peptides with
≥91% confidence were excluded from the final data set. The
peptides and proteins identified in this study are listed in
Supplementary Table 1 (Supporting Information). In Experi-
ment 1 (healthy volunteers) using the above criteria, 428
proteins were identified and successfully quantified with a
protein FDR of 2.8% using the method of Käll et al.,
15 284 of
these proteins were identified with no less than 2 peptides
(Supplementary Table 1). Proteins quantified with one peptide
generally have a larger variance than those with more than one
peptide but we observed no statistically significant difference
(Welch’s test p = 0.08).
The same q-value strategy was applied to Experiments 2 and
3 (pancreatic cancer patient samples) in order to minimize the
FDR for protein identification after searching against a target-
decoy database. In Experiment 2 (day 0), 396 (2.6% FDR) and
Experiment 3 (day 7), 374 (2.8% FDR) proteins were
identified and quantified (Supplementary Table 1, Supporting
Information). Some of these proteins have been observed in the
literature to span over 6 orders of magnitude in plasma protein
concentration (Figure 1A and Methods), including intracellular,
low abundance proteins such as fructose-bisphosphate aldolase
B, a cytosolic protein and Interleukin 6 receptor (IL6-R). As an
example of our proteomic penetration, IL6-R has been
recorded at a concentration of 453 pg/mL in serum (about 9
pM).
22 Supplementary Table 2 (and references therein,
Supporting Information) highlights examples of some of the
proteins identified together with their relative abundance in
plasma.
Biological and Technical Variance in 8 Channel Isobaric
Tagging Plasma Proteomics
We next sought to understand the bias caused by technical and
biological variation.
23 The need for a robust statistical design at
each stage of analysis in quantitative proteomic profiling
experiments is paramount. Technical variation was addressed
by analysis of duplicate samples prepared from healthy controls
(Experiment 1, Figure 1B). We showed a high correspondence
and statistically significant correlation between all technical
replicate labels in this study (p < 0.0001) as summarized in
Supplementary Figure 2 and Supplementary Table 3
(Supporting Information).
The distribution of technical variation is illustrated in
Supplementary Figure 3A (Supporting Information). It can
be said to resemble a Gaussian distribution but has heavier
tailing. As proposed by Breitwieser et al.,
24 technical variation of
iTRAQ data can be modeled as a Cauchy distribution. In this
study, however, it was found that Cauchy distribution did not
provide satisfactory fitting therefore a Gaussian approximation
was carried out on truncated data (see below for detail). The
accuracy and amount of data that fell within an acceptable error
range contained in the technical replicates are summarized in
Table 2. Here all the protein ratios were log2 transformed and
the data were categorized into groups similar to those proposed
by Gan et al.,
25 with variation cut-offs between 0 and 100% of
the expression data. In order to estimate the technical variance
of the data, a Gaussian approximation was made to the
distribution of technical variation. The approximation removed
the largest and smallest 1% protein ratios and fitted the
Table 1. Use of a Target-Decoy Database Search of the Experiment 1 Data Set Using Different q-Value Thresholds
a
q-value threshold
PSMs Quantified Peptides Quantified Proteins
Target Decoy FDR Target Decoy FDR Target Decoy FDR
None 69040 16266 0.24 7947 56 0.007 462 31 0.067
0.05 30672 1614 0.05 7763 53 0.007 459 29 0.063
0.01 21900 230 0.01 6918 26 0.004 428 12 0.028
0.001 18828 77 0.002 6208 2 0.0003 391 2 0.005
aThe number of target and decoy Peptide Spectral Matches (PSMs), quantified peptides and quantified proteins are shown for four choices of q-
value threshold together with the calculated FDR (no threshold indicates the ProteinPilot default output).
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0.3 was observed representing a 95% confidence interval of
±0.59 for technical variation in log space. This variance level
will be used for sample size calculations.
In contrast to technical variation, biological variation is
protein, patient and disease dependent. The distributions of
within- and between-person variations in Experiment 1 are
illustrated in Supplementary Figure 3B and C (Supporting
Information). These distributions were clearly asymmetric and
can be challenging to model with existing theoretical
distributions. In this study, the biological variance was
calculated as a spread of typical variation values such as the
70th percentile, 85th percentile and maximum variation seen in
the biological replicates, similar to what has been proposed by
Yang and Speed.
26 In doing this, the observed within- and
between-person variation were categorized using the same
method as described for the technical replicates (Table 2).
Greater variation was observed between person A and person B
in the study than within each individual at two different time-
points. It was clear that the expression level of the majority of
the proteins (∼80%) varied only to a limited extent.
Sample sizes for clinical proteomic trial design were then
calculated using α = 0.05 and 1-β = 0.8/0.7, which represent
the common choices for significance and power analyses. The
effect sizes (changes in protein abundance) were taken as
log2(1.7) and log2(2). These values are chosen to represent
possible fold change cut-offs in proteomic studies from
previous cell line-based studies. The technical variance and
the biological variance were calculated using the method
described above. The number of technical replicates of interest
in each class was 1, 2, and 4. Required sample sizes were
calculated according to the equation described in the Methods
and the results are summarized in Table 3. It is clear that the
variation of protein quantities has a dramatic effect on the
number of patients that would be required in each group to
adequately power a study. For example, for an experiment with
2 technical replicates per patient and a minimum required
power of 0.8, 5 patients were required to consider a 1.7 fold
change to be significant for proteins with variances not
exceeding 70th percentile (70% least variant proteins). The
required patient number increases to 14 for 80% proteins (least
variant) and rises dramatically to 575 to cover all proteins.
Observing a larger change in protein abundance, having more
technical replicates per patient or reducing the power required
for the study would allow a smaller number of patients to be
required. In many clinical trials, as little as 3 patients per cohort
have been recruited. According to our calculation, this would be
sufficient to detect a 2 fold change with a power of 0.8 for 70%
of proteins (70% least variant). However, if a study is required
to detect more variant proteins, clearly at least 6 patients per
cohort would be beneficial.
Application of Acquired Power Analysis Data to Material
Gathered in a Clinical Trial
To test the validity of our method we applied our workflow to
samples from a clinical trial in which two ‘baseline’ pretreat-
ment samples from 3 patients with pancreatic cancer were
taken one week apart and analyzed over two iTRAQ
experiments (Figure 1B, Experiment 2, day 0 samples;
Experiment 3, day 7 samples). According to our a priori
power calculation using healthy volunteers, the patient group
size would allow us to detect 2-fold changes with a power of 0.8
for 70% of proteins (least variant). Thus in Experiment 2 and 3,
we aimed to verify this with a post hoc power analysis using
Table 2. Number of Proteins Identified (% of Total) with
Different Variation Cut-offs for Technical and Biological
Replicates
a
variation of log2
protein ratio
technical replicate
(% of total)
within person
(% of total)
between person
(% of total)
±10% 37 63 53
±20% 61 69 61
±30% 74 75 69
±40% 83 81 74
±50% 88 84 79
±60% 92 87 82
±70% 94 88 85
±80% 96 90 87
±90% 97 92 89
±100% 98 94 90
aUsing data obtained in Experiment 1 the accuracy and amount of
data that fell within various error ranges was calculated. Between
person and within person variation listed here were derived from the
observed data by removing the variance component from technical
variation.
Table 3. Estimated Sample Sizes Required Per Group
a
variance
effect size 1-β number of replicates 70th percentile 75th percentile 80th percentile 85th percentile maximum
log2(1.7) 0.7 1 5 8 12 17 453
2 4 7 11 16 452
4 4 6 10 15 452
log2(1.7) 0.8 1 7 10 15 21 576
2 5 9 14 20 575
4 5 8 13 19 574
log2(2.0) 0.7 1 3 5 7 10 266
2 3 4 6 10 265
4 2 4 6 9 264
log2(2.0) 0.8 1 4 6 9 13 338
2 3 5 8 12 337
4 3 5 8 12 337
aUsing variance data obtained from Experiment 1 (healthy volunteers) sample sizes are reported for several choices of effect size and variance level.
Sample sizes required are per group. To see an effect size greater than a 2 fold change, 3 samples per group (for e.g. 3 pre-treatment vs. 3 post-
treatment) with 2 technical replicates would be sufficient for proteins with 70% variance with a power of 0.8.
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are pretreatment.
In Experiment 2 (day 0), 396 proteins were identified and
quantified and in Experiment 3 (day 7), 374 proteins. There
were 493 unique proteins altogether and 277 of them were
present across both data sets. In total across all three iTRAQ
experiments, 576 unique proteins were identified and
quantified, of which 244 were present in all experiments. The
iTRAQ protein ratios for the replicate pooled reference samples
in both Experiments 2 and 3 were compared to assess
experimental reproducibility across two separate runs of our
workflow. Bland-Altman test for the agreement between these
experimental replicate pools showed good agreement and
therefore no significant differences were found using Pitman’s
test for differences in variance (n = 268, p = 0.085, r = −0.106)
(Figure 2). Therefore the method allowed for the direct
comparison of protein ratios across multiple iTRAQ experi-
ments via pooled reference samples, such as would be required
in any longitudinal clinical study. It also indicates that technical
variance present in the experiments, which is essential for
carrying out the post hoc power analysis, can be approximated as
the average of technical variance present in each individual
iTRAQ experiment.
We investigated the fold changes of proteins quantified in
both PACER experiments to identify proteins that may be
differentially expressed over a 7 day period pretreatment. As the
within-person variances of Experiment 2 and 3 were not
available, the variance we derived in Experiment 1 was applied
in the analysis of Experiment 2 and 3. A protein is considered
differentially expressed if its variation within the technical
replicates is smaller than the 95% CI defined by the technical
variance, whereas its changes of expression level over 7 days
period is larger than the 95% CI defined by the technical and
within person variance. In total, 29 proteins showed significant
changes in at least one patient (Table 4). It was apparent that
Patient D had considerably more differentially expressed
proteins than the other two patients, although clinical data
for the three patients over the 7 day period does not indicate
any obvious confounding factors that may have led to the large
changes.
The largest change observed was in Peroxiredoxin II, where a
14-fold increase was observed after 7 days in Patient D, and a
smaller yet also significant increase was observed in Patient E.
According to the record from Universal Protein Resource
(UniProt, http://www.uniprot.org/), this protein may be
involved in signaling cascades of growth factors and tumor
necrosis factor-alpha and is relevant to antiapoptotic processes.
Western blotting for Peroxiredoxin II confirmed this protein to
be changing, using Coagulation Factor XIII B Chain Precursor
as a loading control as this was found to be unchanged across
all 3 patients at both time-points in the proteomic analysis
(Figure 3).
According to the observed variance, none of the proteins
listed in Table 4 changed significantly for all patients (2 sided t
test, data not shown). Those showing highest significance and
power however included: Ig alpha-1 chain C region (IGHA1),
Receptor-type tyrosine-protein phosphatase gamma (PTPRG)
and Endoplasmin (HSP90B1). This gives an example of the
approach that can be used with 8 channel isobaric tagging for
clinical proteomics associated with underpinning clinically
relevant power analysis. We stress no novel biomarker is
immediately apparent from this study, as expected, but
Hsp90B1 is a member of the hsp90 family of molecular
chaperones, whose inhibition by geldanamycin-derived com-
pounds can activate the unfolded protein response and led to
cell death in melanoma cells, exposing a potential route to
novel anticancer treatments.
Figure 2. Bland-Altman plot for pooled reference reproducibility across iTRAQ experiments 2 and 3 (PACER day 0 and PACER day 7 clinical
samples). Total of 3 patients, each with duplicate sample at day 0 and day 7 contributing equally to a pooled reference of 12 samples. Proteins that
were identified and quantified in experiments 2 and 3 and originating from the pooled reference sample as defined by the incorporation of iTRAQ
labels 113 and 114 were analyzed for the agreement in log2 iTRAQ ratios (ideally equivalent between both experiments). The agreement was
calculated by the mean of the two measurements versus the difference in values, thus the smaller the difference the greater the reproducibility. The
limits of agreement are shown by the average difference ±1.96 Std.
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were listed in Supplementary Table 4 (Supporting Informa-
tion). Clearly, most proteins have very high variance (>85
percentile), a feature which is primarily due to between person
variation and as such these can hardly be valid candidates for
biomarkers (see Discussion section for more detail). For the
proteins with less variance, the number of patients required to
reach a 70% power estimated using post hoc and a priori power
analysis were compared as illustrated in Supplementary Figure
4. Considerable agreement can be seen between the two
methods, confirming the validity of the a priori power analysis.
■ DISCUSSION
There is a clear clinical need for novel predictive, prognostic
and/or pharmacodynamic biomarkers in easily sourced material
such as plasma. The MS-based method that we have described
provides a robust platform to compare multiple proteins
simultaneously, to allow identification of novel biomarkers with
clinical utility. By use of iTRAQ tagging in conjunction with
extensive statistical testing during data analysis, we have
validated a workflow that is applicable to large scale
longitudinal clinical trials. Furthermore, the experimental
design which includes the use of a pooled reference sample
run in duplicate for each iTRAQ experiment clearly
demonstrates the utility of this methodology to compare fold
changes in protein expression across multiple experiments.
Ernoult et al.
27 employed an iTRAQ methodology in parallel
workflows utilizing immunodepletion or hexapeptide ligand
library enrichment to identify 243 and 228 proteins with at least
2 peptides giving a combined total of 313 proteins. The
inclusion of single peptide protein identifications would have
increased these numbers to 332 and 320 for the immunode-
pleted and hexapeptide enrichment methods employed,
respectively. Kolla et al.
28 have used 4-plex isobaric tagging to
analyze maternal plasma in Down’s Syndrome pregnancies,
identifying 187 proteins. Pernemalm et al.
29 identified and
quantified 300 proteins in an adenocarcinoma plasma study and
193 proteins in a pancreatic cancer study. Thus our approach,
which identified 576 unique proteins in 3 iTRAQ runs, is
statistically rigorous, yields more protein identifications and has
the benefit of 8 samples being analyzed per run. Our data
showed MS variance to be low and comparable to that reported
elsewhere.
30,31 The variation levels we reported showed the
number of intricate steps involved in our experimental
workflow to be robust and reproducible. A study on all
potential cancer biomarkers found in the literature showed 49%
were present at <10 ng/mL in plasma.
32 Therefore our
identification of IL6-R, which is present at subng/mL amounts
(picomolar levels) in plasma, indicates that our discovery
approach has the capacity to uncover potential biomarkers,
especially in the context of studies on patients undergoing
clinical intervention with pre- and post-treatment samples
collected longitudinally. We were also able to confirm changes
in Peroxiredoxin II by Western blotting, showing that this
protein was up-regulated in Patient D and E (Figure 3). This
further validates our workflow design and gives confidence that
we can identify novel biomarkers of predictive, prognostic or
other clinical use. In addition to this, members of the
Peroxiredoxin family (including II) have been linked to
pancreatic
33,34 and other cancers.
35,36
It has been suggested that for the determination of reliable
identification and quantification of a protein by MS it is
necessary for at least two peptides to be identified. However, it
is recognized that this may result in the loss of potentially
interesting small or low abundance proteins. The inclusion of
single peptide data has been debated
37 and it has been
suggested that a two-peptide or more rule should be replaced
by peptide identifications based on thresholds derived from a
more statistically robust estimation of error rates.
38 This
supports the use of our stringent q-value
14 based statistical
approach to determine peptide confidence levels in order to
minimize the number of false positive identifications. By
extending our FDR calculations to provide each PSM with its
own measure of significance, while accounting for multiple
testing this approach provides a robust assessment of the
proportion of significant PSMs that turn out to be false
positives. This enables the inclusion of single peptide protein
identifications and thus maximizes the potential to identify
novel low abundance biomarkers for clinical utility.
In this study, the blood proteomes from the pancreatic
cancer patients analyzed showed obvious differences. Among
the 29 proteins that are differentially expressed in at least one
Table 4. Proteins with Differential Expression in the PACER
Study between Pretreatment Day 0 (Experiment 2) and Day
7 (Experiment 3)
a
protein names
patient C,
day 7:0
patient D,
day 7:0
patient E,
day 7:0
Anti-(ED-B) scFV (Fragment) 1.395 0.081 0.663
ALDH1A1 Retinal dehydrogenase 1 1.099 3.420 1.469
APOL1 Isoform 2 of Apolipoprotein L1 1.059 0.347 0.901
CA1 Carbonic anhydrase 1 1.542 9.579 1.758
CETP Isoform 1 of Cholesteryl ester
transfer protein
1.561 2.031 1.081
CFP Properdin 1.206 2.412 1.257
CRP Isoform 1 of C-reactive protein 1.658 0.383 1.312
FETUB Fetuin-B 0.953 0.361 1.034
GAPDH Glyceraldehyde 3-phosphate
dehydrogenase
0.750 2.107 1.207
GOT1 Aspartate aminotransferase,
cytoplasmic
1.227 2.637 1.017
HGFAC Hepatocyte growth factor
activator
0.802 2.117 1.595
HSP90B1 Endoplasmin 0.592 0.377 0.634
KRT5 Keratin, type II cytoskeletal 5 0.515 0.477 0.696
PARK7 Protein DJ-1 1.572 3.599 1.444
PDLIM1 PDZ and LIM domain
protein 1
1.044 0.333 0.520
PFN1 Profilin-1 0.947 2.771 1.785
PRDX6 Peroxiredoxin-6 1.412 5.408 1.492
PTPRG Isoform 1 of Receptor-type
tyrosine-protein phosphatase gamma
1.829 2.557 1.351
SAA2 Serum amyloid A protein 1.151 0.312 0.764
TALDO1 Transaldolase 1.082 3.046 1.154
TPI1 Isoform 1 of Triosephosphate
isomerase
0.906 2.137 1.738
TMSB4X TMSB4X protein (Fragment) 0.378 0.382 0.797
PRDX2 Peroxiredoxin-2 1.643 14.362 5.921
CAT Catalase 0.947 8.028 2.132
HBA1 Hemoglobin subunit alpha 1.740 10.522 2.904
HBB Hemoglobin subunit beta 1.580 8.881 3.275
HBD Hemoglobin subunit delta 1.579 8.691 2.429
IGHA1 cDNA FLJ90170 fis 1.678 1.937 2.062
PDLIM7 Isoform 1 of PDZ and LIM
domain protein 7
1.516 0.954 2.204
aProteins identified to be differentially expressed in at least one patient
are listed in the table and the significant changes are indicated in bold
italic.
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whereas only 7 were found in Patient E and none in Patient C.
No protein changes significantly in all three patients. This is,
however, not a surprise because all samples used in Experiment
2 and 3 are pretreatment and there is no indication of clinical
difference, such as disease progression, during this period. Thus
the proteins that were found differentially expressed are more
likely to reflect the clinical condition of each individual rather
than act as biomarkers for pancreatic cancer. Although we did
observe proteins that may be directly relevant to cancer
(prognosis, treatment or response), such as HSP90B1, which is
worth further investigation in future studies including post
treatment patient samples, this study has highlighted the
absolute requirement for measurement of baseline changes in
the plasma proteome of patients prior to treatment to
distinguish true treatment-related effects.
Typically, iTRAQ proteomics data sets as well as other
-omics data sets require high costs (money, time, etc) to
produce, especially in experiments involving clinical samples
from patients. It is essential to find out the minimum number of
patients required to provide enough findings. In this study, we
aimed just to clarify the use of power analysis in the context of
complex isobaric tagging or relative quantification mass
spectrometry, and the purpose of power analysis was expressed
as one would find in a well designed clinical study: with the
expected fold changes, to determine the number of patients
required for a proportion of least variant proteins to have
sufficient statistical power to make the study give insight. In a
typical biomarker discovery experiment, variant proteins are
inherently less likely to be valid candidates for a universally
applied biomarker. We can propose that 6 patients per cohort,
allowing for 2 fold changes plus 70% power for 80% of the least
variant proteins, will be a sufficient starting point for a robust
biomarker discovery experiment. It asks for experimental
capacity that is entirely tractable with the current technology,
and maintains a reasonable level of expected statistical power.
Following candidate biomarkers identified by this method,
targeted investigations may be carried out on additional patient
samples that may also be required in order to verify proteins
with higher variance or to obtain greater statistical power.
We stress that the number of patients required to get
sufficient statistical power has been calculated by both a priori
and post hoc power analysis. Comparison showed considerable
agreement between the two results (Supplementary Figure 4,
Supporting Information) for proteins with lesser variance
(<85th percentile), which are of primary interest in biomarker
studies. Essentially, such agreement indicates that despite
differences in experimental condition, disease type, etc., the
variance range for the majority of proteins does not vary
significantly. Therefore the results from the a priori power
analysis (Table 3) can be applied universally for future iTRAQ
experiments.
In this paper, we have described a framework by which
clinical proteomic study designs can minimize the FDR in
protein identification and quantification, leading to thorough
statistical assessment of technical and biological variation on a
study by study basis. This replaces the use of arbitrary
thresholds based upon variance levels reported in other studies
which may be completely unrelated. It is critical to provide a
robust assessment of both technical and biological variance, and
in doing so here we have highlighted the importance of
accounting for these errors during data analysis. Thus, we have
validated the methodology for clinical trial proteomics and
provide a power analysis solution which falls realistically into
study design parameters for clinical trials.
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Figure 3. Uncropped Western blots for levels of Peroxiredoxin II and Coagulation Factor XIII B Chain Precursor in undepleted patient plasma.
Protein levels are shown in relation to the pooled reference and SH-SY5Y lysates were used as a positive control.
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